2021 NICE指南:艰难梭菌感染的抗菌药物处方(NG.199)

2021-07-23 英国国家卫生与临床优化研究所 NICE官网

2021年7月,英国国家卫生与临床优化研究所 (NICE)发布了艰难梭菌感染的抗菌药物处方指南,指南规定了社区和医院内成人,青少年以及年龄≥72h的婴幼儿艰难梭菌感染的抗菌药物处方策略,目的是优

中文标题:

2021 NICE指南:艰难梭菌感染的抗菌药物处方(NG.199)

英文标题:

NICE guideline [NG199]:Clostridioides difficile infection: antimicrobial prescribing

发布日期:

2021-07-23

简要介绍:

2021年7月,英国国家卫生与临床优化研究所 (NICE)发布了艰难梭菌感染的抗菌药物处方指南,指南规定了社区和医院内成人,青少年以及年龄≥72h的婴幼儿艰难梭菌感染的抗菌药物处方策略,目的是优化抗生素应用减少耐药性的产生。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 NICE指南:艰难梭菌感染的抗菌药物处方(NG.199).pdf)] GetToolGuiderByIdResponse(projectId=1, id=602661c0021a08c3, title=2021 NICE指南:艰难梭菌感染的抗菌药物处方(NG.199), enTitle=NICE guideline [NG199]:Clostridioides difficile infection: antimicrobial prescribing, guiderFrom=NICE官网, authorId=0, author=, summary=2021年7月,英国国家卫生与临床优化研究所 (NICE)发布了艰难梭菌感染的抗菌药物处方指南,指南规定了社区和医院内成人,青少年以及年龄&ge;72h的婴幼儿艰难梭菌感染的抗菌药物处方策略,目的是优, cover=https://img.medsci.cn/2021731/1627737858949_2020535.jpg, journalId=0, articlesId=null, associationId=85, associationName=英国国家卫生与临床优化研究所, associationIntro=英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence)是NHS的组织,设在伦敦和曼彻斯特。NICE成立于1999年4月1日,目标是确保每个英格兰和威尔士人平等享有NHS医疗的机会。NICE制定指南,设定质量标准,管理国家数据库,为NHS、当地权威部门和其他组织提供指南。, copyright=0, guiderPublishedTime=Fri Jul 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年7月,英国国家卫生与临床优化研究所 (NICE)发布了艰难梭菌感染的抗菌药物处方指南,指南规定了社区和医院内成人,青少年以及年龄&ge;72h的婴幼儿艰难梭菌感染的抗菌药物处方策略,目的是优化抗生素应用减少耐药性的产生。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=3951, tagName=艰难梭菌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=3951, guiderKeyword=艰难梭菌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12221, appHits=123, showAppHits=0, pcHits=606, showPcHits=12098, likes=0, shares=9, comments=8, approvalStatus=1, publishedTime=Sat Jul 31 22:52:04 CST 2021, publishedTimeString=2021-07-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Jul 31 21:25:39 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 18:27:26 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 NICE指南:艰难梭菌感染的抗菌药物处方(NG.199).pdf)])
2021 NICE指南:艰难梭菌感染的抗菌药物处方(NG.199).pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1015217, encodeId=a4a0101521e8f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55495473976, createdName=ms7000000320809932, createdTime=Tue Sep 07 00:24:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010917, encodeId=6751101091e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/bed0b3f96f164c29bb553417bd81ed39/22e18fd963054cd8967b0fd25b4415eb.jpg, createdBy=a6474751676, createdName=bjszxyyyll, createdTime=Tue Aug 24 10:51:15 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010408, encodeId=333310104087b, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb6f4777421, createdName=kaixing1407, createdTime=Sun Aug 22 21:47:21 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008653, encodeId=97a21008653b0, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:43:46 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007688, encodeId=9a19100e688e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb725566333, createdName=ms1000001821280113, createdTime=Fri Aug 13 18:51:36 CST 2021, time=2021-08-13, status=1, ipAttribution=)]
    2021-09-07 ms7000000320809932

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1015217, encodeId=a4a0101521e8f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55495473976, createdName=ms7000000320809932, createdTime=Tue Sep 07 00:24:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010917, encodeId=6751101091e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/bed0b3f96f164c29bb553417bd81ed39/22e18fd963054cd8967b0fd25b4415eb.jpg, createdBy=a6474751676, createdName=bjszxyyyll, createdTime=Tue Aug 24 10:51:15 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010408, encodeId=333310104087b, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb6f4777421, createdName=kaixing1407, createdTime=Sun Aug 22 21:47:21 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008653, encodeId=97a21008653b0, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:43:46 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007688, encodeId=9a19100e688e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb725566333, createdName=ms1000001821280113, createdTime=Fri Aug 13 18:51:36 CST 2021, time=2021-08-13, status=1, ipAttribution=)]
    2021-08-24 bjszxyyyll

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1015217, encodeId=a4a0101521e8f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55495473976, createdName=ms7000000320809932, createdTime=Tue Sep 07 00:24:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010917, encodeId=6751101091e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/bed0b3f96f164c29bb553417bd81ed39/22e18fd963054cd8967b0fd25b4415eb.jpg, createdBy=a6474751676, createdName=bjszxyyyll, createdTime=Tue Aug 24 10:51:15 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010408, encodeId=333310104087b, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb6f4777421, createdName=kaixing1407, createdTime=Sun Aug 22 21:47:21 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008653, encodeId=97a21008653b0, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:43:46 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007688, encodeId=9a19100e688e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb725566333, createdName=ms1000001821280113, createdTime=Fri Aug 13 18:51:36 CST 2021, time=2021-08-13, status=1, ipAttribution=)]
    2021-08-22 kaixing1407

    学习了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1015217, encodeId=a4a0101521e8f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55495473976, createdName=ms7000000320809932, createdTime=Tue Sep 07 00:24:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010917, encodeId=6751101091e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/bed0b3f96f164c29bb553417bd81ed39/22e18fd963054cd8967b0fd25b4415eb.jpg, createdBy=a6474751676, createdName=bjszxyyyll, createdTime=Tue Aug 24 10:51:15 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010408, encodeId=333310104087b, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb6f4777421, createdName=kaixing1407, createdTime=Sun Aug 22 21:47:21 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008653, encodeId=97a21008653b0, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:43:46 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007688, encodeId=9a19100e688e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb725566333, createdName=ms1000001821280113, createdTime=Fri Aug 13 18:51:36 CST 2021, time=2021-08-13, status=1, ipAttribution=)]
    2021-08-17 DR.Fu SIR

    好好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1015217, encodeId=a4a0101521e8f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55495473976, createdName=ms7000000320809932, createdTime=Tue Sep 07 00:24:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010917, encodeId=6751101091e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/bed0b3f96f164c29bb553417bd81ed39/22e18fd963054cd8967b0fd25b4415eb.jpg, createdBy=a6474751676, createdName=bjszxyyyll, createdTime=Tue Aug 24 10:51:15 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010408, encodeId=333310104087b, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb6f4777421, createdName=kaixing1407, createdTime=Sun Aug 22 21:47:21 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008653, encodeId=97a21008653b0, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:43:46 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007688, encodeId=9a19100e688e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb725566333, createdName=ms1000001821280113, createdTime=Fri Aug 13 18:51:36 CST 2021, time=2021-08-13, status=1, ipAttribution=)]
    2021-08-13 ms1000001821280113

    1

    展开1条回复

拓展阅读

2009 ESCMID:艰难梭菌感染 (CDI)治疗指南

欧洲临床微生物与感染性疾病学会(ESCMID,European Society of Clinical Microbiology and Infectious Diseases) · 2009-12-01

2013 ESCMID:艰难梭菌感染 (CDI)治疗指南(更新版)

欧洲临床微生物与感染性疾病学会(ESCMID,European Society of Clinical Microbiology and Infectious Diseases) · 2013-10-05

2014 CPS立场声明:儿童艰难梭菌感染

加拿大儿科学会(CPS,Canadian Paediatric Society) · 2014-01-30

2014 EAST实践管理指南:手术治疗艰难梭菌相关性疾病的时机和类型

美国东部创伤外科学会(EAST,The Eastern Association for the Surgery of Trauma) · 2014-11-06

2015 ASCRS实践参数:艰难梭菌感染的管理

美国结肠和直肠外科医师学会(ASCRS,American Society of Colon and Rectal Surgeons) · 2015-01-01

2016 ESCMID指南:艰难梭菌感染的诊断

欧洲临床微生物与感染性疾病学会(ESCMID,European Society of Clinical Microbiology and Infectious Diseases) · 2016-08-01